Ars Pharmaceuticals, INC Form 4 insider transactions

Justin Chakma, Chief Business Officer of ARS Pharmaceuticals, exercised stock options and sold shares over three days in December 2024.

Justin Chakma, Chief Business Officer of ARS Pharmaceuticals, engaged in multiple stock option exercises and sales over two days, resulting in a net change in his holdings.

Director Laura Shawver of ARS Pharmaceuticals executed multiple stock transactions, including option exercises and sales, under a pre-arranged 10b5-1 trading plan.

Eric Karas, Chief Commercial Officer of ARS Pharmaceuticals, executed multiple stock option exercises and sales under a pre-arranged trading plan.

ARS Pharmaceuticals' Chief Business Officer, Justin Chakma, sold a total of 100,000 shares of common stock over three days.

ARS Pharmaceuticals CEO, Richard E. Lowenthal, sold 100,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, sold 100,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, sold a portion of her shares through a pre-arranged 10b5-1 trading plan.

ARS Pharmaceuticals CEO, Richard E. Lowenthal, sold a portion of his holdings in the company's common stock through a pre-arranged 10b5-1 trading plan.

Deerfield Funds and James E. Flynn have sold a significant number of ARS Pharmaceuticals shares across multiple transactions, reducing their overall holdings.

Kathleen D. Scott, CFO of ARS Pharmaceuticals, exercised stock options and sold 12,500 shares of common stock at $16 per share on October 16, 2024, while also correcting a previous reporting error regarding shares held in a trust.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, sold shares of common stock on October 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Richard Lowenthal, CEO of ARS Pharmaceuticals, sold shares of common stock on October 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, sold 100,000 shares of common stock on October 8, 2024, as disclosed in a Form 4 filing with the SEC.

Richard Lowenthal, CEO of ARS Pharmaceuticals, sold 100,000 shares of common stock on October 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Eric Karas, Chief Commercial Officer of ARS Pharmaceuticals, exercised stock options and sold 10,000 shares of common stock on September 18, 2024.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, sold 100,000 shares of common stock on September 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Richard Lowenthal, CEO of ARS Pharmaceuticals, sold 100,000 shares of common stock on September 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, executed sales of common stock on September 10, 2024, according to a recent SEC Form 4 filing.

Richard Lowenthal, CEO of ARS Pharmaceuticals, sold 100,000 shares of common stock on September 10, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Peter Thompson reported selling 83,695 shares of ARS Pharmaceuticals (SPRY) common stock on August 26, 2024.

OrbiMed Advisors LLC, a significant shareholder in ARS Pharmaceuticals, Inc. (SPRY), sold 83,695 shares of common stock on August 26, 2024, at an average price of $13 per share.

Director Peter A. Thompson reports selling shares of ARS Pharmaceuticals (SPRY) across several transactions between August 21 and August 23, 2024.

OrbiMed Advisors LLC, along with related entities, sold shares of ARS Pharmaceuticals (SPRY) between August 21 and August 23, 2024.

Brian Dorsey, COO of ARS Pharmaceuticals, exercised stock options and sold 50,000 shares of common stock at $15 per share on August 20, 2024, according to a Form 4 filing.

Eric Karas, Chief Commercial Officer of ARS Pharmaceuticals, exercised stock options and sold 10,000 shares of common stock on August 19, 2024.

Kathleen D. Scott, CFO of ARS Pharmaceuticals, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, executed multiple sales of common stock on August 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Richard Lowenthal, CEO of ARS Pharmaceuticals, executed multiple sales of common stock on August 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Brian Dorsey, Chief Operating Officer of ARS Pharmaceuticals, exercised stock options and sold 30,000 shares of common stock at $13 per share on August 13, 2024, according to a Form 4 filing.